Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene - PubMed (original) (raw)

Review

Patient preferences and perspectives regarding reducing alcohol consumption: role of nalmefene

Amandine Luquiens et al. Patient Prefer Adherence. 2014.

Abstract

Alcohol use disorder is a major public health issue. The absolute mortality burden of alcohol-attributable death has increased over the last 20 years. However, access to care remains very poor and many people with alcohol use disorder are untreated. The main limiting factor for access to care in alcohol use disorder appears to be the reluctance to engage in abstinence. Risk reduction is a developing approach in the treatment of alcohol use disorders, drawing its inspiration, with quite a delay, from the decades-long dominant approach in other substance use disorders. A paradigm shift has recently occurred that places more of an emphasis on reducing alcohol as a therapeutic strategy for patients with alcohol use disorder, to better meet the patients' preferences and needs. The development and recent approval of nalmefene, in alcohol-dependent adults with a high drinking risk level, contributes to enlarging the therapeutic arsenal for alcohol dependence, strengthening the legitimacy of alcohol reduction strategies.

Keywords: alcohol use disorder; harm reduction; patients’ satisfaction; therapeutic goal.

PubMed Disclaimer

Similar articles

• [Benefits in reducing alcohol consumption: how nalmefene can help].
  Bendimerad P, Blecha L. Bendimerad P, et al. Encephale. 2014 Dec;40(6):495-500. doi: 10.1016/j.encep.2014.10.012. Epub 2014 Nov 22. Encephale. 2014. PMID: 25454365 Review. French.
• A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
  Laramée P, Millier A, Rahhali N, Cristeau O, Aballéa S, François C, Chalem Y, Toumi M, Rehm J. Laramée P, et al. Appl Health Econ Health Policy. 2016 Aug;14(4):493-505. doi: 10.1007/s40258-016-0248-z. Appl Health Econ Health Policy. 2016. PMID: 27283839
• [Four cases of alcoholic liver cirrhosis in alcohol-dependent patients treated with nalmefene].
  Tamaki K. Tamaki K. Nihon Shokakibyo Gakkai Zasshi. 2021;118(1):93-100. doi: 10.11405/nisshoshi.118.93. Nihon Shokakibyo Gakkai Zasshi. 2021. PMID: 33431755 Japanese.
• Safety of nalmefene for the treatment of alcohol use disorder: an update.
  López-Pelayo H, Zuluaga P, Caballeria E, Van den Brink W, Mann K, Gual A. López-Pelayo H, et al. Expert Opin Drug Saf. 2020 Jan;19(1):9-17. doi: 10.1080/14740338.2020.1707802. Epub 2019 Dec 30. Expert Opin Drug Saf. 2020. PMID: 31868031
• [Reduction in alcohol consumption: therapeutic goal in alcohol dependence treatment].
  Higuchi S, Saito T. Higuchi S, et al. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2013 Feb;48(1):17-31. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2013. PMID: 23659002 Review. Japanese.

Cited by

• Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies.
  Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, Dematteis M, Mann K, Aubin HJ. Rolland B, et al. CNS Neurosci Ther. 2016 Jan;22(1):25-37. doi: 10.1111/cns.12489. CNS Neurosci Ther. 2016. PMID: 26768685 Free PMC article.
• Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
  Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F. Palpacuer C, et al. PLoS Med. 2015 Dec 22;12(12):e1001924. doi: 10.1371/journal.pmed.1001924. eCollection 2015 Dec. PLoS Med. 2015. PMID: 26694529 Free PMC article. Review.
• Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.
  Fitzgerald N, Angus K, Elders A, de Andrade M, Raistrick D, Heather N, McCambridge J. Fitzgerald N, et al. Addiction. 2016 Aug;111(8):1477-87. doi: 10.1111/add.13438. Epub 2016 Jun 5. Addiction. 2016. PMID: 27262594 Free PMC article. Review.
• In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene.
  Xie X, Lin W, Xing C, Yang Y, Chi Q, Zhang H, Li Y, Li Z, Yang Y, Yang Z, Li M. Xie X, et al. PLoS One. 2015 May 4;10(5):e0125953. doi: 10.1371/journal.pone.0125953. eCollection 2015. PLoS One. 2015. PMID: 25938514 Free PMC article.
• Evaluation in alcohol use disorders - insights from the nalmefene experience.
  Naudet F, Palpacuer C, Boussageon R, Laviolle B. Naudet F, et al. BMC Med. 2016 Aug 18;14(1):119. doi: 10.1186/s12916-016-0664-9. BMC Med. 2016. PMID: 27534932 Free PMC article.

References

1. 1. Roerecke M, Rehm J. Alcohol use disorders and mortality: a systematic review and meta-analysis. Addiction. 2013;108(9):1562–1578. - PubMed
2. 1. Rehm J, Shield KD. Global alcohol-attributable deaths from cancer, liver cirrhosis, and injury in 2010. Alcohol Res. 2013;35(2):174–183. - PMC - PubMed
3. 1. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223–2233. - PubMed
4. 1. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858–866. - PMC - PubMed
5. 1. Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ. Recovery from DSM-IV alcohol dependence: United States, 2001–2002. Addiction. 2005;100(3):281–292. - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Dove Medical Press
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations